Shandong Buchang Pharmaceuticals (603858.SS) Earnings Analysis

Shandong Buchang Pharmaceuticals (603858.SS) has no confirmed upcoming earnings date. Trailing P/E 45.14.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 603858.SS next report earnings?

No confirmed upcoming earnings date is currently scheduled for 603858.SS. This page updates as the calendar is published.

603858.SS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2025-09-290.2282 CNYn/an/an/a
2025-06-300.3023 CNYn/an/an/a
2025-04-25-0.81669 CNYn/an/an/a
2025-03-310.2899 CNYn/an/an/a
2024-10-280.076 CNYn/an/an/a

603858.SS valuation and analyst view

Trailing P/E45.14
Trailing EPS0.35537 CNY
Price / book1.63
Dividend yield2.47%
Market cap16.87B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Shandong Buchang Pharmaceuticals (603858.SS)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 603858.SS. This page updates as the calendar is published.

Did 603858.SS beat earnings last quarter?

Consensus estimate data was not available for 603858.SS's 2025-09-29 report.

What is 603858.SS's current P/E ratio and EPS?

603858.SS trades at a trailing P/E of 45.14 on trailing EPS of 0.3553658199409067 CNY.

What do analysts rate 603858.SS?

603858.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.